Olmesartan Medoxomil/Amlodipine/Hct Innovis (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine/Hct Innovis, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood‑pressure control beyond a single agent.

GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hct Innovis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil/Amlodipine/HCT Innovis is used in cardiovascular therapy to manage high blood pressure through multiple mechanisms. - Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. - Hypertensive urgency (when oral therapy is appropriate): helps achieve target pressures safely. - Combination therapy for patients with resistant hypertension: simplifies regimens and improves adherence.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after standing. - Fatigue: general tiredness. - Increased urination: due to diuretic component. - Flushing: transient warmth sensation.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips or throat. - Severe electrolyte imbalance: notably low potassium or sodium. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: abnormal liver enzymes. - Severe hypotension: symptomatic low blood pressure. - Allergic skin reactions: rash, Stevens‑Johnson syndrome.

Patients should be evaluated for specific health conditions and monitored during therapy. - Renal impairment: adjust monitoring, may need dose modification. - Hepatic disease: use with caution, monitor liver function. - Electrolyte disturbances: check potassium and sodium levels regularly. - Pregnancy: avoid use, especially in the second and third trimesters. - Concomitant use with other antihypertensives: risk of excessive blood‑pressure lowering. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine/HCT Innovis can interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): may cause severe hypotension and renal dysfunction. - Potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole): increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Lithium: may increase lithium concentrations. - Antidiabetic agents: blood‑glucose may fall, requiring dose adjustment.